Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.

ACS Med Chem Lett

Center for Investigational Therapeutics, Huntsman Cancer Institute, 2000 Circle of Hope, Salt Lake City, UT 84112, United States.

Published: December 2011

AI Article Synopsis

  • The receptor tyrosine kinase AXL is a promising target for cancer treatment due to its overexpression and role in tumor growth and metastasis.
  • Researchers developed a homology model of AXL's catalytic domain to screen for small molecule inhibitors.
  • They created a series of 2,4,5-trisubstituted pyrimidines that effectively inhibited AXL and reduced growth in pancreatic cancer cell lines, with an impressive IC(50) of 19 nM.

Article Abstract

The receptor tyrosine kinase AXL has emerged in recent years as an potential oncology target due to its over expression in several types of cancers coupled with its ability to promote tumor growth and metastasis. In order to identify small molecule inhibitors of AXL, we built a homology model of its catalytic domain to virtually screen and identify scaffolds displaying an affinity for AXL. Further computational and structure-based design resulted in the synthesis of a series of 2,4,5-trisubstitued pyrimidines which demonstrated potent inhibition of AXL in vitro (IC(50) 19 nM) and strongly inhibited the growth of several pancreatic cell lines.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3254106PMC
http://dx.doi.org/10.1021/ml200198xDOI Listing

Publication Analysis

Top Keywords

design synthesis
8
axl
5
synthesis biological
4
biological evaluation
4
evaluation series
4
series novel
4
novel axl
4
axl kinase
4
kinase inhibitors
4
inhibitors receptor
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!